ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
66,057.69
1.34%
S&P 500
5,745.14
0.00%
Dow Jones
42,494.61
0.76%
US Dollar vs Yen
142.7215
-1.64%
Brent Oil
71.405
0.64%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Catalyst Pharmaceuticals Inc (CPRX)

  7. Catalyst Pharmaceuticals Inc (CPRX) ニュース

CPRX

Catalyst Pharmaceuticals (CPRX)

Catalyst Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:CPRX
日付受信時刻ニュースソース見出しコード企業名
2024/09/2621 : 42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/09/2419 : 00GlobeNewswire Inc.Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in JapanNASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/08/2306 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/08/2105 : 42Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/08/2021 : 03GlobeNewswire Inc.Catalyst Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/08/1406 : 01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/08/1000 : 24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/08/0805 : 32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/08/0805 : 11GlobeNewswire Inc.Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/07/2705 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/07/2421 : 05GlobeNewswire Inc.Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in CanadaNASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/07/2221 : 03GlobeNewswire Inc.Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024NASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/06/1206 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/06/0800 : 17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/06/0606 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/06/0606 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/06/0423 : 41Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/06/0401 : 22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/06/0105 : 50Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/06/0105 : 47Edgar (US Regulatory)Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]NASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/06/0105 : 46Edgar (US Regulatory)Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]NASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/06/0105 : 43Edgar (US Regulatory)Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]NASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/05/3105 : 43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/05/3102 : 41GlobeNewswire Inc.Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®NASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/05/2821 : 03GlobeNewswire Inc.Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024NASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/05/2206 : 28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/05/0905 : 54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/05/0905 : 16GlobeNewswire Inc.Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/05/0905 : 06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CPRXCatalyst Pharmaceuticals Inc
2024/05/0121 : 00GlobeNewswire Inc.Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024NASDAQ:CPRXCatalyst Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:CPRX

最近閲覧した銘柄

USOTC
DTEGY
Deutsche Telekom (QX)
CCOM
US500
US 500
CCOM
US30
US 30
COIN
BTCUSD
Bitcoin
USOTC
BASFY
BASF (QX)
AMEX
XLE
Energy Select Sector SPDR
CCOM
SILVER
SILVER
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
BAC
Bank of America
NYSE
DIS
Walt Disney
FX
USDEUR
US Dollar vs Euro
NASDAQ
TSLA
Tesla
AMEX
XLV
Health Care Select Sector
COIN
XRPUSD
Ripple
PM
XAUUSD
Gold vs US Dollar
AMEX
SPY
SPDR S&P 500
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有